Galantamine (Reminyl®) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the HERG current

European Journal of Pharmacology

Volumn 681, Issue 1-3, 2012, Pages 68-74

  Vigneault, Patrick ^a,b   Bourgault, Sarah ^a,b   Kaddar, Nisrin ^a,b   Caillier, Bertrand ^a,b   Pilote, Sylvie ^b   Patoine, Dany ^b   Simard, Chantale ^a,b   Drolet, Benoit ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Action potential; Galantamine; HERG blocker; QT interval prolongation; Ventricular repolarization

Indexed keywords

GALANTAMINE; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ1; CHOLINESTERASE INHIBITOR; VOLTAGE GATED POTASSIUM CHANNEL;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; ELECTROCARDIOGRAM; EMBRYO; FEMALE; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE PRESSURE; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; PATCH CLAMP; PHARMACOLOGICAL BLOCKING; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; ACTION POTENTIAL; ANIMAL; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ELECTROCARDIOGRAPHY; GUINEA PIG; INTRAPERITONEAL DRUG ADMINISTRATION; LONG QT SYNDROME;

ACTION POTENTIALS; ANIMALS; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; GALANTAMINE; GUINEA PIGS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAPERITONEAL; KCNQ1 POTASSIUM CHANNEL; LONG QT SYNDROME; MALE; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, VOLTAGE-GATED;

EID: 84858709247     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.02.002     Document Type: Article

References (15)

1. R. Bachus, U. Bickel, T. Thomsen, I. Roots, and H. Kewitz The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6 Pharmacogenetics 9 1999 661 668 (Pubitemid 30011930)
2. A. Burns, R. Bernabei, R. Bullock, A.J. Cruz Jentoft, L. Frolich, C. Hock, M. Raivio, E. Triau, M. Vandewoude, A. Wimo, E. Came, B. Van Baelen, G.L. Hammond, J.C. van Oene, and S. Schwalen Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial Lancet Neurol. 8 2009 39 47
3. W.J. Crumb Jr., S. Ekins, R.D. Sarazan, J.H. Wikel, S.A. Wrighton, C. Carlson, and C.M. Beasley Jr. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis Pharm. Res. 23 2006 1133 1143 (Pubitemid 43946136)
4. M.Q. Dong, C.P. Lau, Z. Gao, G.N. Tseng, and G.R. Li Characterization of recombinant human cardiac KCNQ1/KCNE1 channels (I (Ks)) stably expressed in HEK 293 cells J. Membr. Biol. 210 2006 183 192 (Pubitemid 44306223)
5. B. Drolet, M. Khalifa, P. Daleau, B.A. Hamelin, and J. Turgeon Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval Circulation 97 1998 204 210 (Pubitemid 28124679)
6. M. Eichelbaum, H.K. Kroemer, and M.F. Fromm Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs Adv. Drug Deliv. Rev. 27 1997 171 199 (Pubitemid 27417872)
7. M.R. Farlow Clinical pharmacokinetics of galantamine Clin. Pharmacokinet. 42 2003 1383 1392 (Pubitemid 38045842)
8. A.A. Fisher, and M.W. Davis Prolonged QT interval, syncope, and delirium with galantamine Ann. Pharmacother. 42 2008 278 283 (Pubitemid 351238578)
9. Galantamine Hydrobromide (Reminyl™) Monograph 2008 Janssen-Ortho Inc.
10. F. Huang, K.C. Lasseter, L. Janssens, T. Verhaeghe, H. Lau, and Q. Zhao Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together J. Clin. Pharmacol. 42 2002 1341 1351 (Pubitemid 35373604)
11. M. Malik, and A.J. Camm Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling Drug Saf. 24 2001 323 351 (Pubitemid 32417533)
12. M.W. Nelson, and R.W. Buchanan Galantamine-induced QTc prolongation J. Clin. Psychiatry 67 2006 166 167
13. B.H. Robert, and J.M. Spivey Galantamine and QTc prolongation J. Clin. Psychiatry 68 2007 169 170
14. D.M. Roden Acquired long QT syndromes and the risk of proarrhythmia J. Cardiovasc. Electrophysiol. 11 2000 938 940 (Pubitemid 30663004)
15. Q. Zhao, M. Brett, N. Van Osselaer, F. Huang, A. Raoult, A. Van Peer, T. Verhaeghe, and R. Hust Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects J. Clin. Pharmacol. 42 2002 1002 1010 (Pubitemid 34920798)